Procept BioRobotics Seeks $164M To Go Public

The company is selling 6,556,000 shares at $25 a share to support the commercialization of its AquaBeam robotic system for minimally invasive treatment of benign prostatic hyperplasia.

IPO

PROCEPT BioRobotics is going public to expand the marketing staff supporting its Aquablation technology for minimally invasive urology surgery and support future research and development activities.

Less than three months after the Redwood City, CA-based company announced an $85m series G financing round, it offered 6,556,000...

More from Financing

More from Business